Cellular Immunotherapy Market Size & Growth Forecast 2027–2036, By Segments (End-use, Therapy Type, Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cellular Immunotherapy Market size was valued at USD 15.06 billion in 2026 and is anticipated to grow at a 21.29% CAGR from 2027 to 2036, reaching USD 103.77 billion by 2036. The industry revenue for 2027 is assessed at USD 17.76 billion.
Base Year Value (2026)
USD 15.06 billion
CAGR (2027-2036)
21.29%
Forecast Year Value (2036)
USD 103.77 billion
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036
Cellular Immunotherapy Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America leads through established treatment infrastructure, specialized oncology centers, strong commercialization of approved therapies, and efficient patient access supporting routine clinical adoption.
- Asia Pacific is projected to grow at a 23.98% CAGR, supported by expanding cancer care capacity, rising therapy adoption, increasing clinical activity, and investment in domestic manufacturing capabilities.
-
Segment Momentum:
- Hospitals lead due to controlled inpatient infrastructure, multidisciplinary clinical teams, and full treatment pathway management from infusion to post-care monitoring, essential for operationally intensive cellular immunotherapy delivery.
- CAR T Cell Therapy leads both largest and fastest-growing adoption due to strong oncology integration and established clinical workflows, supported by expanding specialist expertise and structured treatment environments.
-
Market Expansion Drivers:
- Rising global cancer prevalence accelerating adoption of advanced cellular immunotherapy treatments.
- Expanding clinical trial pipeline and product approvals strengthening commercialization of cell-based therapies.
- Increasing investment in allogeneic off-the-shelf therapies improving scalability of immunotherapy manufacturing.
-
Leading Market Participants:
Key players in the cellular immunotherapy market include Bristol-Myers Squibb Company (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), GlaxoSmithKline plc (United Kingdom), AstraZeneca plc (United Kingdom), Pfizer Inc. (United States), Johnson & Johnson (United States), Celyad Oncology SA (Belgium).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2026 Market Size: USD 15.06 billion
- 2027 Estimated Market Size: USD 17.76 billion.
- Projected Market Size: USD 103.77 billion by 2036
- Growth Forecasts: 21.29% CAGR (2027-2036)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospitals (End-use) | CAR T Cell Therapy (Therapy Type) | B-cell Malignancies (Indication)
- Emerging Opportunity Segment: Cancer Institutes (End-use) | CAR T Cell Therapy (Therapy Type) | B-cell Malignancies (Indication)
Market Growth Drivers and Industry Trends
Rising global cancer prevalence accelerating adoption of advanced cellular immunotherapy treatments
The increasing burden of cancer is strengthening demand for innovative treatment approaches, supporting the cellular immunotherapy market as healthcare providers and researchers pursue therapies capable of targeting malignant cells through immune-based mechanisms. Cellular immunotherapies can offer highly specialized treatment approaches by using immune cells that are modified, selected, or expanded to recognize and attack cancer cells, creating opportunities in areas where conventional treatment approaches may have limitations. Growing clinical experience with cell-based therapies is also contributing to greater understanding of patient selection, treatment protocols, manufacturing requirements, and management of therapy-related considerations, supporting broader development across oncology applications.
Expanding clinical trial pipeline and product approvals strengthening commercialization of cell-based therapies
A broader clinical development pipeline is supporting the cellular immunotherapy market by expanding the range of investigational approaches being evaluated across cancer types and treatment settings. Progression from clinical research toward regulatory approvals can strengthen confidence in cell-based therapeutic platforms and encourage healthcare systems to develop the infrastructure required for treatment delivery, including specialized clinical centers, cell processing capabilities, and patient monitoring processes. As more therapies demonstrate clinical utility, developers are gaining opportunities to refine manufacturing workflows and treatment protocols while extending cellular immunotherapy approaches into additional indications and patient populations, increasing the commercial relevance of cell-based treatment platforms.
Increasing investment in allogeneic off-the-shelf therapies improving scalability of immunotherapy manufacturing
Investment in allogeneic cellular therapies is addressing an important scalability consideration within the cellular immunotherapy market by supporting treatment models designed for broader availability rather than relying exclusively on individualized patient-specific manufacturing. Off-the-shelf approaches can simplify production planning and potentially improve consistency by enabling cells to be prepared in advance, subject to appropriate safety, compatibility, and quality requirements. Research and development efforts focused on donor-derived cell sources, cell engineering, cryopreservation, and manufacturing automation are helping advance these platforms, while improvements in production processes can support more standardized handling and distribution of cellular therapy products.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer prevalence accelerating adoption of advanced cellular immunotherapy treatments | 2.00% | High | North America, Europe | High | Near Term |
| Expanding clinical trial pipeline and product approvals strengthening commercialization of cell-based therapies | 1.90% | High | North America, Asia Pacific | High | Mid Term |
| Increasing investment in allogeneic off-the-shelf therapies improving scalability of immunotherapy manufacturing | 1.60% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
Largest Market Share in 2026
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)
North America dominated the cellular immunotherapy market in 2026, supported by advanced healthcare infrastructure, strong oncology research capabilities, and substantial investment in innovative cancer treatments. The region benefits from sophisticated clinical development ecosystems and increasing integration of personalized medicine into cancer care. Continued progress in cell-based therapeutic approaches, specialized treatment facilities, and research-driven healthcare systems is reinforcing regional adoption and supporting the commercialization of advanced immunotherapy solutions.
Asia Pacific is positioned as the fastest-growing region, driven by expanding healthcare infrastructure, increasing oncology treatment needs, and growing investment in advanced therapeutic technologies. Improvements in specialized clinical capabilities and greater adoption of personalized treatment approaches are creating favorable conditions for cellular immunotherapy development. Rising healthcare expenditure and efforts to expand access to innovative cancer therapies are further supporting the region's emerging role in this market.
Key Country Insights
The U.S. cellular immunotherapy market is characterized by active commercialization efforts and expanding treatment infrastructure for advanced cell therapies. Healthcare providers and developers in the U.S. are prioritizing manufacturing scalability, patient access pathways, and next-generation therapies targeting broader oncology indications.
Japan is emphasizing cellular immunotherapy approaches that align with personalized medicine and regenerative healthcare initiatives. The market in Japan is increasingly focused on streamlining development pathways and supporting collaborations that accelerate the transition of novel therapies into routine clinical settings.
South Korea is investing in manufacturing infrastructure and technology platforms that support cellular immunotherapy development and production. Companies in South Korea are actively pursuing partnerships and contract manufacturing opportunities to strengthen their position within the advanced therapy value chain.
Germany's cellular immunotherapy market benefits from strong links between academic research and specialized treatment centers. Stakeholders in Germany are concentrating on integrating innovative cell therapies into clinical practice while strengthening manufacturing capabilities and regulatory readiness for advanced therapeutic products.
France continues to advance cellular immunotherapy through research institutions and specialized oncology networks. The country's priorities include improving patient access to innovative therapies and expanding clinical capabilities that facilitate the adoption of personalized cell-based treatments across healthcare systems.
Italy's cellular immunotherapy market is progressing through targeted investments in oncology centers and translational research initiatives. Healthcare institutions in Italy are focusing on strengthening treatment delivery capabilities and fostering collaborations that support the introduction of advanced cell therapies.
Segment Leadership and Growth Trends
End-use Segment Analysis: Hospitals (Largest Segment) vs Cancer Institutes (Fastest-Growing Segment)
The cellular immunotherapy market was led by hospitals in 2026, reflecting their central role in administering advanced immune-based treatments and managing patients requiring complex oncology care. Hospitals typically provide the specialized infrastructure, multidisciplinary expertise, diagnostic capabilities, and monitoring resources needed for cellular immunotherapy, supporting their strong utilization of these therapies. The growing integration of personalized treatment approaches into hospital-based cancer care is further reinforcing demand for sophisticated cellular therapy services.
Cancer institutes are emerging as a rapidly expanding end-use setting as their specialized focus on oncology supports concentrated adoption of advanced cellular immunotherapies. These institutions are well positioned to manage complex treatment pathways, patient selection, intensive monitoring, and specialized post-treatment care. Increasing emphasis on precision oncology and the development of dedicated treatment infrastructure are strengthening the role of cancer institutes in expanding access to cellular immunotherapy.
Therapy Type Segment Analysis: CAR T Cell Therapy (Largest & Fastest-Growing Segment)
CAR T cell therapy held the largest share of the cellular immunotherapy market in 2026 while also representing the fastest-growing therapy type, supported by its highly targeted approach to treating certain cancers. The therapy modifies a patient's immune cells to recognize and attack specific cancer cells, creating strong clinical interest in situations where conventional treatment options may be inadequate. Continued advances in cell engineering, treatment protocols, patient selection, and manufacturing processes are supporting broader adoption and strengthening the position of CAR T cell therapy within cellular immunotherapy.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| End-use | Hospitals, Cancer Institutes, Others | Hospitals | Cancer Institutes |
| Therapy Type | CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others | CAR T Cell Therapy | CAR T Cell Therapy |
| Indication | B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others | B-cell Malignancies | B-cell Malignancies |
Read our Research ApproachCompetitive Landscape and Market Positioning
Top players in the cellular immunotherapy market:
1. Bristol-Myers Squibb Company (United States)
2. Novartis AG (Switzerland)
3. Gilead Sciences Inc. (United States)
4. F. Hoffmann-La Roche Ltd (Switzerland)
5. Merck KGaA (Germany)
6. GlaxoSmithKline plc (United Kingdom)
7. AstraZeneca plc (United Kingdom)
8. Pfizer Inc. (United States)
9. Johnson & Johnson (United States)
10. Celyad Oncology SA (Belgium)
Rapid scientific progress is driving the cellular immunotherapy market, with increasing investment in advanced cell engineering, precision therapies, and innovative manufacturing technologies. Ongoing research is expanding treatment possibilities while improving therapeutic effectiveness and scalability.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Gilead Sciences | Apr-26 | Gilead Sciences successfully completed its US$7.8 billion acquisition of Arcellx. By securing full ownership of the investigational BCMA-directed CAR-T therapy anito-cel, Gilead eliminates existing royalty and profit-sharing obligations and integrates Arcellx’s proprietary D-Domain platform into its Kite oncology business, aiming to accelerate the commercialization of next-generation cell therapies for multiple myeloma. |
| Montefiore Einstein | Apr-26 | Montefiore Einstein inaugurated the Manny and Joanne Chirico Cellular Immunotherapy Laboratory. This new facility is designed to bolster translational research infrastructure, specifically accelerating the development and clinical translation of novel cell-based cancer therapies. The investment reflects a strategic commitment to converting academic breakthroughs into scalable, effective immunotherapeutic treatments for complex oncology indications. |
| UNC | May-26 | Researchers at the University of North Carolina (UNC) developed a next-generation cellular immunotherapy approach targeting acute myeloid leukemia (AML). The new methodology aims to improve both the safety profile and potency of engineered immune cells, addressing critical challenges in current AML treatment landscapes and providing a potential framework for enhanced clinical efficacy in both adult and pediatric patient populations. |
| Xcellbio | Mar-25 | Xcellbio partnered with Royal Perth Hospital to establish an automated manufacturing workflow for tumor-infiltrating lymphocyte (TIL) therapies. By focusing on the standardization and scalability of TIL production—a historically complex process—the collaboration seeks to lower barriers to clinical adoption and facilitate the wider availability of advanced cell-based solid tumor treatments. |
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
